Minimal Residual Disease Pipeline Appears Robust With 8+ Key Pharma Companies Actively Working in the Therapeutics Segment | DelveInsight

DelveInsight's, "Minimal Residual Disease Pipeline Insight 2025" report provides comprehensive insights about 8+ companies and 8+ pipeline drugs in Minimal Residual Disease pipeline landscape. It covers the Minimal Residual Disease pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Minimal Residual Disease pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Discover the latest drugs and treatment options in the Minimal Residual Disease Pipeline. Dive into DelveInsight's comprehensive report today! @ Minimal Residual Disease Pipeline Outlook- https://www.delveinsight.com/sample-request/minimal-residual-disease-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Key Takeaways from the Minimal Residual Disease Pipeline Report
• In May 2025, Janssen Research & Development LLC announced a study is to evaluate conversion rate to minimal residual disease (MRD) negativity following the addition of daratumumab to lenalidomide relative to lenalidomide alone, when administered as maintenance treatment to anti-cluster of differentiation 38 (CD38) treatment naive participants with newly diagnosed multiple myeloma who are MRD positive as determined by next generation sequencing (NGS) at screening, following high-dose therapy (HDT) and autologous stem cell transplant (ASCT).
• In May 2025, H. Lee Moffitt Cancer Center and Research Institute announced a study is to see if people whose Acute myeloid leukemia (AML) is being successfully treated with azacitidine or decitabine in combination with venetoclax can discontinue this chemotherapy for some period of time after a year of treatment without increasing the likelihood that their AML will return.
• In May 2025, Novartis Pharmaceuticals conducted a study was to investigate whether nilotinib treatment can be safely suspended with no recurrence of CML in selected patients who responded optimally on this treatment.
• In May 2025, Pfizer announced a study is to evaluate whether elranatamab monotherapy can provide clinical benefit compared to lenalidomide monotherapy (control) in participants with newly diagnosed multiple myeloma after undergoing autologous stem cell transplant. In Part 1 and Part 2 of the study, participants in the study will either receive elranatamab (arm A and C) as an injection under the skin at the study clinic or lenalidomide orally once daily at home (arm B). Participation in the study will be approximately five years.
• DelveInsight's Minimal Residual Disease Pipeline report depicts a robust space with 8+ active players working to develop 8+ pipeline therapies for Minimal Residual Disease treatment.
• The leading Minimal Residual Disease Companies such as Genentech, AmMax Bio, Elicio Therapeutics, Precigen Inc., and others.
• Promising Minimal Residual Disease Pipeline Therapies such as Midostaurin, Lenalidomide, Elranatamab, Mitoxantrone, Gemtuzumab ozogamicin, Palbociclib, Avelumab and others.

Stay ahead with the most recent pipeline outlook for Minimal Residual Disease. Get insights into clinical trials, emerging therapies, and leading companies with DelveInsight @ Minimal Residual Disease Treatment Drugs- https://www.delveinsight.com/sample-request/minimal-residual-disease-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Minimal Residual Disease Emerging Drugs Profile
• AMB-066: AmMax Bio
AMB-066 is a potent monoclonal antibody targeting the colony stimulating factor 1 receptor (CSF1R) that will be clinically evaluated for the treatment of patients with CRC MRD. The antibody has been tested in approximately 200 patients and healthy subjects across five clinical trials for other indications via intravenous, intra-articular and subcutaneous injections. It has been shown to be generally safe and well tolerated in all studies. Currently, the drug is in Phase II stage of its clinical trial for the treatment of Minimal residual disease.

• ELI-002: Elicio Therapeutics
Elicio's lead product candidate, ELI-002, is a structurally novel investigational AMP cancer vaccine that targets cancers that are driven by mutations in the KRAS-gene-a prevalent driver of many human cancers. ELI-002 is comprised of two powerful components that are built with Elicio's AMP technology consisting of AMP-modified mutant KRAS peptide antigens and ELI-004, an AMP-modified CpG oligodeoxynucleotide adjuvant that is available as an off-the-shelf subcutaneous administration. Currently, the drug is in Phase I stage of its clinical trial for the treatment of Minimal residual disease.

The Minimal Residual Disease Pipeline Report Provides Insights into
• The report provides detailed insights about companies that are developing therapies for the treatment of Minimal Residual Disease with aggregate therapies developed by each company for the same.
• It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Minimal Residual Disease Treatment.
• Minimal Residual Disease Companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
• Minimal Residual Disease Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Minimal Residual Disease market

Explore groundbreaking therapies and clinical trials in the Minimal Residual Disease Marketed and Pipeline Drugs. Access DelveInsight's detailed report now! @ New Minimal Residual Disease Drugs- https://www.delveinsight.com/sample-request/minimal-residual-disease-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Minimal Residual Disease Companies
Genentech, AmMax Bio, Elicio Therapeutics, Precigen Inc., and others.

Minimal residual disease pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
• Oral
• Intravenous
• Subcutaneous
• Parenteral
• Topical

Minimal Residual Disease Products have been categorized under various Molecule types such as
• Recombinant fusion proteins
• Small molecule
• Monoclonal antibody
• Peptide
• Polymer
• Gene therapy

Unveil the future of Minimal Residual Disease Treatment. Learn about new drugs, pipeline developments, and key companies with DelveInsight's expert analysis @ Minimal Residual Disease Market Drivers and Barriers- https://www.delveinsight.com/sample-request/minimal-residual-disease-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Scope of the Minimal Residual Disease Pipeline Report
• Coverage- Global
• Minimal Residual Disease Companies- Genentech, AmMax Bio, Elicio Therapeutics, Precigen Inc., and others.
• Minimal Residual Disease Pipeline Therapies - Midostaurin, Lenalidomide, Elranatamab, Mitoxantrone, Gemtuzumab ozogamicin, Palbociclib, Avelumab and others.
• Minimal Residual Disease Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
• Minimal Residual Disease Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III

Get the latest on Minimal Residual Disease Therapies and clinical trials. Download DelveInsight's in-depth pipeline report today! @ Minimal Residual Disease Companies, Key Products and Unmet Needs- https://www.delveinsight.com/sample-request/minimal-residual-disease-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Table of Content
1. Introduction
2. Executive Summary
3. Minimal residual disease: Overview
4. Pipeline Therapeutics
5. Therapeutic Assessment
6. Minimal residual disease- DelveInsight's Analytical Perspective
7. Late Stage Products (Phase III)
8. Drug Name: Company Name
9. Mid Stage Products (Phase II)
10. AMB-066: AmMax Bio
11. Early Stage Products (Phase I)
12. ELI-002: Elicio Therapeutics
13. Preclinical and Discovery Stage Products
14. Drug Name: Company Name
15. Inactive Products
16. Minimal residual disease Key Companies
17. Minimal residual disease Key Products
18. Minimal residual disease- Unmet Needs
19. Minimal residual disease- Market Drivers and Barriers
20. Minimal residual disease- Future Perspectives and Conclusion
21. Minimal residual disease Analyst Views
22. Minimal residual disease Key Companies
23. Appendix

List of Top Selling Market Research Reports in 2025

Radiation retinopathy market- https://www.delveinsight.com/sample-request/radiation-retinopathy-market
Immune checkpoints activators market- https://www.delveinsight.com/report-store/immune-checkpoint-inhibitors-market
Cystic fibrosis Market- https://www.delveinsight.com/report-store/cystic-fibrosis-market
Palmoplantar pustulosis market- https://www.delveinsight.com/report-store/palmoplantar-pustulosis-market
Smoking cessation market- https://www.delveinsight.com/report-store/smoking-cessation-and-nicotine-addiction-market
Surgical energy instruments market- https://www.delveinsight.com/report-store/surgical-energy-instruments-electrosurgical-devices-market
Tay-Sachs market- https://www.delveinsight.com/report-store/tay-sachs-disease-market
Attention deficit hyperactivity disorder market- https://www.delveinsight.com/report-store/attention-deficit-hyperactivity-disorder-adhd-market
Medical marijuana market- https://www.delveinsight.com/report-store/medical-marijuana-market
Open angle glaucoma market- https://www.delveinsight.com/report-store/glaucoma-market
Acute myeloid leukemia market- https://www.delveinsight.com/report-store/acute-myeloid-leukemia-aml-market
Asperger syndrome market- https://www.delveinsight.com/report-store/autism-spectrum-disorder-asd-market
Bone growth stimulators market- https://www.delveinsight.com/report-store/bone-growth-stimulators-market
Cardiogenic shock market- https://www.delveinsight.com/report-store/cardiogenic-shock-market
Pacemakers market- https://www.delveinsight.com/report-store/pacemakers-market
Pediatric brain tumor market- https://www.delveinsight.com/report-store/pediatric-brain-tumors-market
Pelizaeus-merzbacher disease market- https://www.delveinsight.com/report-store/pelizaeus-merzbacher-disease-market
Peritoneal carcinomatosis market- https://www.delveinsight.com/report-store/peritoneal-carcinomatosis-pc-market
Pipeline assessment services- https://www.delveinsight.com/consulting/pipeline-assessment-services

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: info@delveinsight.com
Phone: 09650213330
Address: 304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/

This release was published on openPR.